Dispatches from AAPS

Kemwell announces Cirrus to produce trial supplies in 'flexi suite'

By Fiona Barry

- Last updated on GMT

Kemwell announces Cirrus to produce trial supplies in 'flexi suite'

Related tags Manufacturing

Kemwell’s daughter company Cirrus will start manufacturing pharmaceuticals for clinical trials out of a GMP suite set to open in North Carolina.

At the AAPS (American Association of Pharmaceutical Scientists) Annual Meeting in San Diego yesterday, Ninad Deshpanday, President of R&D at Kemwell, told Outsourcing-Pharma.com CDMO Cirrus is set to expand its services from R&D-only to manufacture.

Construction of the flexible GMP room is due to finish in April next year and will manufacture “all types of formulation except sterile products.​”

I’m calling it a flexi suite – what’s so exciting is it’s not only for aerosols or solids. We’re designing it so we can roll in and out equipment in using steel carts on rollers, depending on the dosage form,​” said Deshpanday.

The company will use mostly equipment it already owns for formulation development, meaning funds are only being spent on building a clean room and decking it out with air and water filters, electrical connections and gowns. Cirrus will staff the unit with four employees: two process development workers who will be trained in manufacturing, and a QA head and a facilities manager.


Manufacturing capacity will be for early stage trials only, at a volume of one to 25 litres. “We won’t be able to support a Phase III 2,000-patient clinical from here. That’s when we’ll transfer to Bangalore, where our larger CMO facilities will help.​”

Kemwell bought Cirrus in August last year​, when it developed only aerosol products. Since then, the North Carolina company has expanded to perform contract development for oral products and peptides and proteins.

The Indian company has made a series of investments in recent months to its Bangalore facilities, including an oral solid dose manufacturing plant, and a commercial-scale lyophilisation unit​.

Related news

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Content provided by Formedix | 17-Apr-2023 | White Paper

Companies often have to conduct multiple clinical trials at the same time, which means they've got to be efficient, and compliant with industry regulations....

Related suppliers

Follow us


View more